Redeye comments on Cantargia's fourth quarter report 2025. We discuss the potentially changing treatment landscape after strong data from RAS inhibitors in pancreatic cancer. Cantargia is planning for a pivotal study in 2026, pending the finalisation of the IL1RAP diagnostic and funding. We believe this to be the main trigger for the share this year.
LÄS MER
